Improving efficacy of liver transplantation for hepatocellular carcinoma by comprehensive treatment
10.3969/j.issn.1674-7445.2021.03.001
- VernacularTitle:利用综合治疗措施进一步提高肝癌肝移植疗效
- Author:
Genshu WANG
1
Author Information
1. Department of Hepatic Surgery, Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
- Publication Type:Research Article
- Keywords:
Hepatocellular carcinoma;
Liver transplantation;
Down-staging therapy;
Bridging therapy;
Comprehensive treatment;
Transcatheter arterial chemoembolization (TACE);
Cytotoxic T lymphocyte-associated antigen (CTLA);
Programmed cell death protein 1 (PD-1);
Sorafenib;
Lenvatinib;
Stereotactic body radiation therapy (SBRT);
Tyrosine kinase inhibitors (TKI)
- From:
Organ Transplantation
2021;12(3):249-
- CountryChina
- Language:Chinese
-
Abstract:
Currently, several major challenges still exist in liver transplantation for hepatocellular carcinoma (HCC), including the opportunity of liver transplantation for HCC patients beyond selection criteria, drop-out from the waiting list for HCC patients within selection criteria due to tumor progression and the tumor recurrence after liver transplantation. In recent years, revolutionary efficacy has been achieved in treating advanced HCC by employing systemic drugs, such as lenvatinib and systemic drug-based comprehensive treatment, which also sheds light on the down-staging therapy and bridging therapy for HCC patients listed for liver transplantation, and prevention and treatment of tumor recurrence after liver transplantation for HCC individuals. Systemic drug-based comprehensive treatment probably has the potential to improve the clinical efficacy of liver transplantation for HCC, which deserves in-depth investigation. In this review, we summarize the progress on down-staging therapy, bridging therapy as well as prevention and treatment of tumor recurrence after liver transplantation for HCC individuals, aiming to provide reference for clinical managementof HCC.
